Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 + bevacizumab vs mFOLFOX6 + panitumumab in RAS wild-type unresectable colorectal cancer
jRCT1080222680Phase 3Completed
- Sponsor
- Kohei Shitara
- Start
- Dec 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of panitumumab, bevacizumab, fluorouracil, levoleucovorin and oxaliplatin in colorectal adenocarcinoma, metastatic colorectal adenocarcinoma (mCRC), colorectal cancer (CRC) and 1 more (2 arms), sponsored by Kohei Shitara. Primary endpoint: Overall survival. Started Dec 2014; status: completed.
02
Drugs
panitumumabbevacizumabfluorouracillevoleucovorinoxaliplatin
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)recurrent colorectal cancer
Beyond the preview
Go deeper on jRCT1080222680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222680.